← Back to Search

Cognitive Training

Computerized Cognitive Training for Psychosis (Rem-STEP Trial)

Phase < 1
Recruiting
Led By Caroline Demro, PhD
Research Sponsored by University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, one month follow-up post-intervention
Awards & highlights
No Placebo-Only Group

Summary

This trial will study state representation in young adults with and without a psychiatric diagnosis. The trial will involve some observational tests and a cognitive training clinical trial.

Who is the study for?
This trial is for individuals aged 18-45 with conditions like schizophrenia or mood disorders with psychotic features, fluent in English, and have been stable outside a hospital for at least a month. They must not have severe substance use recently, significant cognitive training experience within the last six months, or other neurological disorders (except autism).
What is being tested?
The study tests two types of computerized cognitive training designed to improve information processing about surroundings in young adults with psychosis compared to those without psychiatric diagnoses.
What are the potential side effects?
Since this trial involves non-invasive computerized cognitive training exercises, there are no direct physical side effects expected from participating. However, participants may experience mental fatigue or stress.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, one month follow-up post-intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, one month follow-up post-intervention for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Performance of Bandit Task Variant
Change in Performance of DPX Task Variant
Secondary study objectives
Brain
Change in Test My Brain Neurocognitive Assessment performance: Matrix Reasoning Z Score
Change in Test My Brain Neurocognitive Assessment performance: Multiracial Emotion Identification Z Score
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Visual Perception TrainingExperimental Treatment1 Intervention
Contains targeted visual perception exercises from BrainHQ's suite of cognitive exercises. This training paradigm is designed to improve state estimation processes at the perceptual input level.
Group II: Visual Cognitive Control TrainingExperimental Treatment1 Intervention
Contains targeted visual cognitive control exercises from BrainHQ's suite of exercises. This training paradigm is designed to enhance state representation stability of visual information.

Find a Location

Who is running the clinical trial?

University of MinnesotaLead Sponsor
1,434 Previous Clinical Trials
1,621,602 Total Patients Enrolled
11 Trials studying Psychosis
1,525 Patients Enrolled for Psychosis
National Institute of Mental Health (NIMH)NIH
2,918 Previous Clinical Trials
2,740,033 Total Patients Enrolled
47 Trials studying Psychosis
10,693 Patients Enrolled for Psychosis
Caroline Demro, PhDPrincipal InvestigatorUniversity of Minnesota Department of Psychiatry and Behavioral Sciences

Media Library

BrainHQ Computerized Cognitive Training - Visual Cognitive Control Training Paradigm (Cognitive Training) Clinical Trial Eligibility Overview. Trial Name: NCT05538832 — Phase < 1
Psychosis Research Study Groups: Visual Perception Training, Visual Cognitive Control Training
Psychosis Clinical Trial 2023: BrainHQ Computerized Cognitive Training - Visual Cognitive Control Training Paradigm Highlights & Side Effects. Trial Name: NCT05538832 — Phase < 1
BrainHQ Computerized Cognitive Training - Visual Cognitive Control Training Paradigm (Cognitive Training) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05538832 — Phase < 1
~12 spots leftby Mar 2025